{"id":"W2595228860","doi":"10.1182/blood.v126.23.4234.4234","title":"Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Dalhousie University; University Health Network; Jewish General Hospital; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Bortezomib; Internal medicine; Dexamethasone; Lenalidomide; Dosing; Multiple myeloma; Pharmacology; Refractory (planetary science); Carfilzomib; Oncology; Gastroenterology; Adverse effect; Urology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007373594,0.0007051976,0.001275064,0.0003645049,0.0002817414,0.0005714578,0.0004821706,0.0003719325,0.001193032],"category_scores_gemma":[0.0004030754,0.0004313045,0.0005305323,0.0004684421,0.0004979747,0.0003612717,0.0002414268,0.00166186,0.0004118976],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006677547,"about_ca_system_score_gemma":0.0006979666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006715885,"about_ca_topic_score_gemma":0.002772136,"domain_scores_codex":[0.9996424,0.0001430502,0.00002773445,0.0000647663,0.00006471123,0.00005734662],"domain_scores_gemma":[0.9997674,0.0000394197,0.0000693879,0.00001925142,0.000009879248,0.00009472125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.266925,0.05436771,0.02381023,0.00082638,0.001455814,0.0005540954,0.0004708719,0.003860067,0.3514607,0.0002320233,0.003105782,0.2929314],"study_design_scores_gemma":[0.09102246,0.756635,0.08877235,0.00005287111,0.0008760225,0.001618259,0.0001480331,0.00338806,0.05029325,0.0001869543,0.006956013,0.0000508423],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956285,0.002576311,0.0003921843,0.0001708712,0.00004293201,0.0001997521,0.0001723895,0.00006215461,0.0007549028],"genre_scores_gemma":[0.9968631,0.0009342877,0.0008322555,0.0001124146,0.00006217404,0.0001196952,0.0003386657,0.000009704363,0.00072775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001275064,"threshold_uncertainty_score":0.004844904,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02609085781535739,"score_gpt":0.278428074502276,"score_spread":0.2523372166869186,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}